Anzeige
Mehr »
Login
Samstag, 11.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
100 % Anstieg in zwei Tagen: Das technische Signal, das Wall Streets Bären in Panik versetzt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
179 Leser
Artikel bewerten:
(0)

Voptica S.L. Announces the appointment of Françoise Ganet & Joe Sullivan, to its Board of Directors

Finanznachrichten News

MURCIA, Spain, March 2, 2022 /PRNewswire/ -- Medical device company Voptica S.L. announced that it has appointed Françoise Ganet & Joe Sullivan to the management board of directors.

Voptica_Logo

"We are very pleased to welcome Françoise and Joe to the board. Both have broad expertise in the ophthalmology and pharmaceutical businesses in which they have lead management positions in consolidated enterprises. I truly believe this will be a new phase for Voptica' s future developments and current products VAO Visual Adaptive Optics Simulator and ArtIOLs, our new inverted meniscus EDOF IOL designed to improve image quality in the periphery," Pablo Artal, PhD, CEO and Co-founder of Voptica.

Françoise Ganet comes with nearly 30 years of extensive experience in pharmaceutical, bio-pharmaceutical, and medical device industries in senior executive positions. Amongst them, 23 years fully dedicated to the ophthalmic space at Alcon.

Her leadership and operating expertise in opening, establishing, and managing over 25 markets in the EU, Central and Eastern Europe, and Russia, will help guide our company in its important work ahead.

"I am thrilled and honored to join the Voptica's board of director at a very interesting time for the company. Voptica have in their portfolio the VAO, the first Compact Adaptive Optics Simulator, an all-in-one device including phoropter, aberrometer and auto-refractometer offering a pre-op visual simulation to target the best visual post-op outcome. The dynamic and innovative team lead by Professor Pablo Artal also developed the ArtIOLs, a non-diffractive EDOF IOL with unique inverted meniscus aspheric shape, conceived to mimic the natural crystalline lens and providing optimized field curvature and improved peripheral vision for patients. Looking forward to joining Voptica in this exciting journey," Françoise Ganet said.

Joe Sullivan, is a strong international business leader and strategist with a proven track record of success in managing international business organizations. He is the CEO of Emmetropes, a global catalyst for innovation and business in Ophthalmology. Prior to Emmetropes Joe was Managing Director of Esteve Pharma and Vice President of Marketing Strategy & Sales at Astra Zeneca in Spain. His roots in Ophthalmology trace back to 10 years at Alcon, where he was Director of Alcon Surgical Spain.

Joe Sullivan added, "I'm delighted to join VOPTICA's Board at this exciting time for the company. Pablo Artal and his Team continue to bring breakthrough innovation to the Ophthalmic space and the new suite of intraocular lenses, ArtIOLs look particularly promising. We're confidently looking forward to the benefits these unique lenses will provide patients and physicians."

About Voptica S.L.

Voptica is an innovative pioneer in the field of Personalized Vision testing and Correction. By bringing to the market VAOÒ, the company's unique visualization instrument, together with ArtIOLsÒ, an unprecedent suite of inverted meniscus shaped EDOF IOLs to improve peripheral vision, Voptica is opening a new era in personalized ophthalmic surgical outcomes.

For more information, please visit: https://voptica.com LinkedIn: @Voptica | Twitter: @Voptica | YouTube: @Voptica | Instagram: @voptica_visual

Contact:

luis.artal@voptica.com
Luis Artal
Marketing Manager at Voptica S.L.
+34 868 954 817

Logo: https://mma.prnewswire.com/media/1589257/Voptica_Logo.jpg

© 2022 PR Newswire
6 Richtige für 2025
Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.